Award

1r-1 Ca125077-01a1

Funder: National Cancer Institute

Funded outputs count: 2

Funder award ID: 1R-1 CA125077-01A1

OpenAlex ID: G1663649573

Quality of Reporting of Serious Adverse Drug Events to an Institutional Review Board: A Case Study with the Novel Cancer Agent, Imatinib Mesylate

2009 · David A. Dorr, Rachel Burdon, et al. · Clinical Cancer Research · 34

Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia

2008 · Charles L. Bennett, Samuel M Silver, et al. · JAMA · 738